Therefore, this study aimed to further our understanding of CEA expression in different pathological subtypes in advanced lung cancer patients and to verify the effects of EGFR mutation status on the prognostic potential of CEA in these patients. The gene discussed is CEACAM5; the disease is lung carcinoma.